Conferences - Results from #200

Viewing 201-220 of 11872 articles

IBCN 2024: Dynamic Monitoring of Circulating Tumor DNA to Predict Prognosis in Muscle-Invasive Bladder Cancer Patients After Radical Cystectomy

IBCN 2024: Retifanlimab Monotherapy as Neoadjuvant Therapy for Patients with Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder: Results from the Multicenter OPTIMUS Umbrella Study

IBCN 2024: Undetectable ctDNA Status Before Radical Cystectomy Predicts Improved Outcomes

IBCN 2024: Keynote Lecture: Inferring Tumor Evolution from Single-Cell Data

IBCN 2024: Comprehensive Genomic Characterization of Early Stage Bladder Cancer

IBCN 2024: Elucidating the Response Rates to Additional BCG: Implications for Clinical Trial Design

ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Non-Prostate

ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate

ESMO 2024: Identification of Bladder Cancer Patients That Could Benefit from Early Post-Cystectomy Immunotherapy Based on Serial Circulating Tumour DNA Testing: Preliminary Results from the TOMBOLA Trial

ESMO 2024: Controversies in Testis Cancer: Escalation or De-escalation?

ESMO 2024: TAR-200 plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Patients with Muscle-Invasive Bladder Cancer Who Are Ineligible for or Refuse Neoadjuvant Cisplatin-Based Chemotherapy: Interim Analysis of SunRISe-4

ESMO 2024: Invited Discussant: JCOG1019, TOMBOLA, and SunRISe-4

ESMO 2024: Empowering Bladder Cancer Care Integrating Patient Preferences and Voices

ESMO 2024: Histology Subtypes (variants) of Bladder Cancer

ESMO 2024: JCOG1019 Phase III Study Comparing the Effectiveness of Watchful Waiting and Intravesical BCG in Patients with High-grade pT1 Bladder Cancer with pT0 on the 2nd Transurethral Resection Specimen

ESMO 2024: Nivolumab plus Chemoradiotherapy in Patients with Non-Metastatic Muscle-Invasive Bladder Cancer, Not Undergoing Cystectomy: A Phase II, Randomized Study by the Hellenic GU Cancer Group.

ESMO 2024: Health-Related Quality of Life from the CheckMate 901 Trial of Nivolumab as First-Line Therapy for Unresectable or Metastatic Urothelial Carcinoma

ESMO 2024: Clinical Prognostic Factors Within the High-Volume Subgroup of Metastatic Hormone Sensitive Prostate Cancer in ENZAMET (ANZUP 1304)

ESMO 2024: Evaluation of Event-Free Survival as a Surrogate Endpoint for Overall Survival in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy

ESMO 2024: HARMONY: A Phase II Study of Niraparib/Abiraterone Acetate plus Prednisone for Hispanic/Latinoand Non-Hispanic Black Patients with Metastatic Hormone Sensitive Prostate Cancer and Deleterious Homologous Recombination Repair Alterations

6
7
8
9
10
11
12
13
14
15